Atlas Trials

Juno Therapeutics, a Subsidiary of Celgene

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Juno Therapeutics, a Subsidiary of Celgene

RecordFirmDate
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04674813)Juno Therapeutics, a Subsidiary of Celgene2021-02-24
A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04394650)Juno Therapeutics, a Subsidiary of Celgene2020-08-18
A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT04231747)Juno Therapeutics, a Subsidiary of Celgene2020-05-21
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (NCT03744676)Juno Therapeutics, a Subsidiary of Celgene2018-11-29
Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) (NCT03483103)Juno Therapeutics, a Subsidiary of Celgene2018-07-27
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771)Juno Therapeutics, a Subsidiary of Celgene2018-02-19
Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (NCT03430011)Juno Therapeutics, a Subsidiary of Celgene2018-02-01
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (NCT03331198)Juno Therapeutics, a Subsidiary of Celgene2017-11-27

Track Juno Therapeutics, a Subsidiary of Celgene automatically

Every clearance here is in the API, with alerts when new ones post.